| Newsletter December 2005 |
ANT Receives FDA 510k clearance for Cognitrace We had the pleasure of meeting at the ANT (Advanced Neuro Technology) booth at the May 2005, APA meeting in Atlanta. As you may recall, we exhibited the Cognitrace EEG/ERP for clinical neuro-psychiatry. I am pleased to inform you that on September 12, 2005, ANT received the FDA 510K clearance to market the Cognitrace system in the United States.ANT has been marketing research EEG/ERP system for several years in North America. With this FDA approval we are excited to offer our products for clinical applications as well. Cognitrace provides a comprehensive, yet user-friendly environment for EEG/ERP acquisition, analysis, and report generation. We believe that the information provided by the system will add an invaluable tool in evaluating patients with diverse neuro-psychiatric presentations. Please feel free to contact me for further information on Cognitrace. In addition, I would be happy to arrange an internet-based demonstration of the system, as well as to discuss its potential value for your clinical practice. |
|